Treatment of metastatic colon cancer: "The times they are A-changing"

Journal of Clinical Oncology

Volumn 31, Issue 16, 2013, Pages 1913-1916

  Kemeny, Nancy E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COLON CANCER; EDITORIAL; HUMAN; LIVER METASTASIS; LIVER RESECTION; METASTATIC COLON CANCER; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; TUMOR VOLUME; COLORECTAL TUMOR; FEMALE; GENETICS; LIVER TUMOR; MALE; NOTE; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84880665721     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.4500     Document Type: Editorial

References (33)

1. Megginson LC: Lessons from Europe for American business. Southwestern Social Science Quarterly 44:3-13, 1963
2. Ye L-C, Liu T-S, Ren L, et al: Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liverlimited metastases. J Clin Oncol 31:1931-1938, 2013
3. Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230:309-318, 1999; discussion 318-321
4. Adam R, Avisar E, Ariche A, et al: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347-353, 2001
5. Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240:644-657, 2004; ; discussion 657-648
6. Ardito F, Vellone M, Cassano A, et al: Chance of cure following liver resection for initially unresectable colorectal metastases: Analysis of actual 5-year survival. J Gastrointest Surg 17:352-359, 2013
7. Nordlinger B, Sorbye H, Glimelius B, et al: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 371:1007-1016, 2008
8. Kemeny NE, Melendez FD, Capanu M, et al: Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 27:3465-3471, 2009
9. Mitry E, Fields AL, Bleiberg H, et al: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: A pooled analysis of two randomized trials. J Clin Oncol 26:4906-4911, 2008
10. Ychou M, Hohenberger W, Thezenas S, et al: A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20:1964-1970, 2009
11. Kemeny N, Huang Y, Cohen AM, et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2039-2048, 1999
12. Kemeny NE, Gonen M: Hepatic arterial infusion after liver resection. N Engl J Med 352:734-735, 2005
13. Lygidakis NJ, Sgourakis G, Vlachos L, et al: Metastatic liver disease of colorectal origin: The value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection - Results of a prospective randomized study. Hepatogastroenterology 48:1685-1691, 2001
14. Kemeny MM, Adak S, Gray B, et al: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - An intergroup study. J Clin Oncol 20:1499-1505, 2002
15. Lorenz M, Müller HH, Schramm H, et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer: German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228:756-762, 1998
16. Rubbia-Brandt L, Giostra E, Brezault C, et al: Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299-304, 2007
17. Masi G, Vasile E, Loupakis F, et al: Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: An updated analysis. J Natl Cancer Inst 103:21-30, 2011
18. Maughan TS, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 377:2103-2114, 2011
19. Tveit KM, Guren T, Glimelius B, et al: Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study. J Clin Oncol 30:1755-1762, 2012
20. Folprecht G, Gruenberger T, Bechstein WO, et al: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 11:38-47, 2010
21. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
22. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 22:1535-1546, 2011
23. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
24. Okines A, Puerto OD, Cunningham D, et al: Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer: First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101:1033-1038, 2009
25. Borner M, Koeberle D, Von Moos R, et al: Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: A randomized phase II trial of the Swiss Group for Clinical Cancer Res SAKK. Ann Oncol 19:1288-1292, 2008
26. Saridaki Z, Androulakis N, Vardakis N, et al: A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: A pilot phase II trial. Br J Cancer 107:1932-1937, 2012
27. Masi G, Loupakis F, Salvatore L, et al: Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: A phase 2 trial. Lancet Oncol 11:845-852, 2010
28. Garufi C, Torsello A, Tumolo S, et al: Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 103:1542-1547, 2010
29. Goéré D, Deshaies I, de Baere T, et al: Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 251:686-691, 2010
30. Bouchahda M, Adam R, Giacchetti S, et al: Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer 115:4990-4999, 2009
31. Gallagher DJ, Capanu M, Raggio G, et al: Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: A retrospective analysis. Ann Oncol 18:1995-1999, 2007
32. Boige V, Malka D, Elias D, et al: Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 15:219-226, 2008
33. Ducreux M, Ychou M, Laplanche A, et al: Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: A trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23:4881-4887, 2005